Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05252988
What this trial is testing

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

Who this might be right for
Early-stage Breast CancerHER2 Positive Breast CancerHormone Receptor Positive
Spanish Breast Cancer Research Group 177
Not applicableLooking for participantsNCT07484087
What this trial is testing

Ablation Compare With Surgery for Early Breast Cancer

Who this might be right for
Breast CancerEarly StageHormone Receptor Positive+1 more
Peking University People's Hospital 264
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07317778
What this trial is testing

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)HR Positive/HER2 Low Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 249
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07676331
What this trial is testing

Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial

Who this might be right for
Hormone-receptor-positive Breast CancerEarly Breast Cancer
Universitaire Ziekenhuizen KU Leuven 168
Not applicableUnknownNCT05801705
What this trial is testing

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Who this might be right for
Hormone-receptor-positive Breast CancerPremenopausal Breast CancerBreast Cancer Patients at Intermediate to High Risk+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 700
Not applicableStudy completedNCT07498413
What this trial is testing

Epidemiology and Treatment of HR+/HER2- Breast Cancer in England

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 218,677
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Early research (Phase 1)Enrolling By InvitationNCT06671691
What this trial is testing

A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)SBRT
Universitat de les Illes Balears 15
Testing effectiveness (Phase 2)Study completedNCT03078751
What this trial is testing

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 54
Not applicableEnrolling By InvitationNCT06791161
What this trial is testing

Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

Who this might be right for
Breast
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 300
Testing effectiveness (Phase 2)Looking for participantsNCT05582499
What this trial is testing

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Who this might be right for
Breast NeoplasmBreast CancerBreast Tumors+7 more
Fudan University 716
Not applicableUnknownNCT05870813
What this trial is testing

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerHormone Receptor Positive Breast Carcinoma
Institut fuer Frauengesundheit 3,000
Large-scale testing (Phase 3)Study completedNCT00309491
What this trial is testing

Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients

Who this might be right for
Early-stage Breast Cancer
Austrian Breast & Colorectal Cancer Study Group 2,021
Not applicableStudy completedNCT01446185
What this trial is testing

Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients

Who this might be right for
Breast Cancer
Genomic Health®, Inc. 100
Not applicableStudy completedNCT00638391
What this trial is testing

Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 1,600
Testing effectiveness (Phase 2)Looking for participantsNCT06517212
What this trial is testing

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsBreast Cancers
Baylor Research Institute 48
Not applicableStudy completedNCT02186470
What this trial is testing

Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerInvasive Ductal Breast CarcinomaInvasive Ductal Breast Carcinoma With Predominant Intraductal Component+7 more
Ohio State University Comprehensive Cancer Center 22
Large-scale testing (Phase 3)Ended earlyNCT05128773
What this trial is testing

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Who this might be right for
Breast Cancer
Sanofi 3
Testing effectiveness (Phase 2)Study completedNCT02413008
What this trial is testing

A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

Who this might be right for
Vaginal Atrophy
ITF Research Pharma, S.L.U. 61
Early research (Phase 1)Looking for participantsNCT06139107
What this trial is testing

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Who this might be right for
Breast Cancer
Mridula George, MD 15
Next Page